| CAS No.: | 2381089-83-2 |
|---|---|
| Formula: | C50h69n15o9 |
| EINECS: | 1308068-626-2 |
| Type: | Pharmaceutical Intermediates |
| Appearance: | Powder |
| Quality: | Technical |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Retatrutide is a triple glucagon, GIP, and GLP-1 receptor agonist. Retatrutide showed glucose control
and weight loss in patients with type 2 diabetes mellitus (T2DM).
What Is Retatrutide?
Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus, obstructive sleep
apnea, osteoarthritis, obesity and non-alcoholic fatty liver disease. The drug candidate is administered through
subcutaneous and intravenous route. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1),
glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is a new molecular entity.
Retatrutide: Are There Any Side Effects?
Although no serious side effects were reported during phase 2 trials, Retatrutide is suspected to give rise to
some common side effects experienced when GLP-1 receptors including constipation, nausea, vomiting,
and diarrhea. In phase 2 clinical trials, researchers also saw a surge in heart rate in adults administered with
a higher Retatrutide dose after 6 months, but the symptoms declined accordingly.
However, side effects can be avoided by using a lower starting dose of Retatrutide.
As of now, Retatrutide is set up for phase 3 clinical trials, and the trials with the participation of thousands of
individuals diagnosed with obesity and other weight-related illnesses won't finish until 2025. During the trials,
researchers will investigate its safety and possible side effects when used for a long time.
While the possibility of Retatrutide's approval to the public is unpredictable, at least by 2026 or 2027, it is
essential to exercise caution when implementing pharmaceutical interventions to lose weight. No weight loss
drug guarantees substantial weight loss unless you adopt healthy lifestyle choices, such as exercising, eating
nutrient-dense, balanced diets, cutting back on sugary and processed foods and beverages, etc.
You Get What You Paid For :
| 2mg | 5mg | 10mg | |
| Semaglutide | $80/Box | $130/Box | $230/Box |
| Tirzepatide | $90/Box | $140/Box | $260/Box |
| Retatrutide | $135/Box | $210/Box | $400/Box |
It's in US Dollar, 10vials per Box. Price is negotiated if order in bulk. Good quality with after-sale
service superior to peers.
Purchasing objects are required to be companies and labs, not for personal use.
Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists,
or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating. One role of GLP-1 is to
prompt the body to produce more isulin, which reduces blood sugar (glucose).
Tirzepatide FDA Approves New Medication for Chronic Weight Management.Tirzepatide (Mounjaro) is used for weight loss and type 2 diabetes in adults. Tirzepatide is a GIP and GLP-1 receptor agonist and works for weight loss by decreasing
your appetite and slowing the movement of food from the stomach into the small intestine, which may make you feel full
more quickly and for a longer period of time. Tirzepatide also decreases blood sugar levels by increasing isulin production
and lowering the amount of sugar the liver makes.
Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity.Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once weekly subcutaneous formulation. It is a long-acting
amylin analogue. Amylin is co-located with isulin in secretory granules and co-secreted with isulin by pancreatic beta cells in response to food intake.
All Peptides For Research Purpose Only, abuse is prohibited.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}